Peg-Asparaginase



Indications and Reactions:

Role Indications Reactions
Primary
Acute Lymphocytic Leukaemia 62.5%
Acute Leukaemia 12.5%
Rigors 12.5%
T-cell Type Acute Leukaemia 12.5%
Urticaria 44.4%
Anaphylactic Reaction 11.1%
Pancreatitis 11.1%
Pleural Effusion 11.1%
Unresponsive To Stimuli 11.1%
Vomiting 11.1%
Secondary
Acute Lymphocytic Leukaemia 44.4%
T-cell Type Acute Leukaemia 20.2%
Product Used For Unknown Indication 10.5%
B Precursor Type Acute Leukaemia 4.7%
Lymphocytic Leukaemia 4.6%
Non-hodgkin's Lymphoma 4.1%
Acute Leukaemia 2.3%
Leukaemia Recurrent 1.9%
Acute Lymphocytic Leukaemia Recurrent 1.6%
Prophylaxis 1.5%
Drug Use For Unknown Indication 0.7%
Pain 0.6%
Infection Prophylaxis 0.6%
Antiemetic Supportive Care 0.5%
Gastrostomy Tube Insertion 0.3%
Nausea 0.3%
Sepsis 0.3%
Pyrexia 0.2%
Vomiting 0.2%
Antifungal Prophylaxis 0.2%
Sepsis 15.2%
Off Label Use 11.4%
Infection 7.6%
Aspartate Aminotransferase Increased 5.1%
Drug Toxicity 5.1%
Post Transplant Lymphoproliferative Disorder 5.1%
Rhabdomyolysis 5.1%
Toxic Encephalopathy 5.1%
Weight Decreased 5.1%
Anal Ulcer 3.8%
Constipation 3.8%
Death 3.8%
Hypoxia 3.8%
Thrombosis 3.8%
Vomiting 3.8%
Caecitis 2.5%
Cerebral Ischaemia 2.5%
Encephalopathy 2.5%
Epilepsy 2.5%
Hypersensitivity 2.5%
Concomitant
Acute Lymphocytic Leukaemia 19.7%
Acute Lymphocytic Leukaemia Recurrent 8.2%
Product Used For Unknown Indication 8.2%
Chemotherapy 6.6%
Prophylaxis 6.6%
B Precursor Type Acute Leukaemia 4.9%
Bone Marrow Conditioning Regimen 4.9%
Nausea 4.9%
Premedication 4.9%
Vomiting 4.9%
Body Temperature Increased 3.3%
Constipation 3.3%
Lymphocytic Leukaemia 3.3%
Pain 3.3%
Prophylaxis Of Nausea And Vomiting 3.3%
T-cell Type Acute Leukaemia 3.3%
Antifungal Prophylaxis 1.6%
Cough 1.6%
Headache 1.6%
Metastases To Meninges 1.6%
Acute Lymphocytic Leukaemia 7.1%
Benign Intracranial Hypertension 7.1%
Concomitant Disease Progression 7.1%
Csf Pressure Increased 7.1%
Febrile Bone Marrow Aplasia 7.1%
Hypotension 7.1%
Intracranial Pressure Increased 7.1%
Lactobacillus Infection 7.1%
Peripheral Sensorimotor Neuropathy 7.1%
Prothrombin Level Decreased 7.1%
Sensory Loss 7.1%
Staphylococcal Infection 7.1%
Stenotrophomonas Infection 7.1%
Vomiting 7.1%